Business Description
Amplia Therapeutics Ltd
ISIN : AU0000023822
Description
Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.53 | |||||
| Equity-to-Asset | 0.84 | |||||
| Debt-to-Equity | 0.15 | |||||
| Debt-to-EBITDA | -0.52 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 8.9 | |||||
| 3-Year EPS without NRI Growth Rate | 8.9 | |||||
| 3-Year FCF Growth Rate | 10.8 | |||||
| 3-Year Book Growth Rate | -11.8 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 44.26 | |||||
| 9-Day RSI | 41.08 | |||||
| 14-Day RSI | 41.1 | |||||
| 6-1 Month Momentum % | -6.1 | |||||
| 12-1 Month Momentum % | -26.67 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.43 | |||||
| Quick Ratio | 3.43 | |||||
| Cash Ratio | 2.06 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -38.8 | |||||
| Shareholder Yield % | -0.42 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -26.96 | |||||
| ROA % | -23.04 | |||||
| ROIC % | -59.61 | |||||
| ROC (Joel Greenblatt) % | -251.45 | |||||
| ROCE % | -26.29 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.86 | |||||
| Price-to-Tangible-Book | 1.88 | |||||
| EV-to-EBIT | -2.14 | |||||
| EV-to-EBITDA | -2.18 | |||||
| EV-to-FCF | -1.59 | |||||
| Price-to-Net-Current-Asset-Value | 2.13 | |||||
| Price-to-Net-Cash | 6.4 | |||||
| Earnings Yield (Greenblatt) % | -46.73 | |||||
| FCF Yield % | -46.18 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Amplia Therapeutics Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | |||
| EPS (TTM) (A$) | -0.023 | ||
| Beta | 0.58 | ||
| Volatility % | 40.8 | ||
| 14-Day RSI | 41.1 | ||
| 14-Day ATR (A$) | 0.004351 | ||
| 20-Day SMA (A$) | 0.071931 | ||
| 12-1 Month Momentum % | -26.67 | ||
| 52-Week Range (A$) | 0.055 - 0.111768 | ||
| Shares Outstanding (Mil) | 199.62 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Amplia Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Amplia Therapeutics Ltd Stock Events
| Event | Date | Price(A$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Amplia Therapeutics Ltd Frequently Asked Questions
What is Amplia Therapeutics Ltd(ASX:ATX)'s stock price today?
The current price of ASX:ATX is A$0.06. The 52 week high of ASX:ATX is A$0.11 and 52 week low is A$0.06.
When is next earnings date of Amplia Therapeutics Ltd(ASX:ATX)?
The next earnings date of Amplia Therapeutics Ltd(ASX:ATX) is .
Does Amplia Therapeutics Ltd(ASX:ATX) pay dividends? If so, how much?
Amplia Therapeutics Ltd(ASX:ATX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers